Investigación y ensayos clínicos

Research grants:

1. “Hepatitis C virus exploits the hepatic lipid pathways: Role of NPC1L1 in HCV infection”. Grant from FONDECYT (National Fund of Science and Technology, Chile). N° 1130357. 2013-2017. Principal Investigator.

2. “Role of extrahepatic replication of hepatitis C virus in the prediction of response to antiviral therapy”. Grant from FONDECYT (National Fund of Science and Technology, Chile). N° 1080323. 2008-2012. Principal Investigator.

3. “Evaluation of Results of the Pilot Program of Hepatitis C Treatment”. Grant from FONIS (National Fund for Health Investigation). 2007-2009. Principal Investigator.

4. “Capture and enrichment of emerging pathogens for multiple and ultra-sensitive diagnostic (USDEP)” (FP6-2005-Lifesciheaalth-7). 2006-2008. Local co-investigator.

5. “Recherches sur le plans diagnostic et physiopathologique chez les Virus Emergents” (JEAI-IRD). 2006-2008. Local co-investigator.

6. “Role of extrahepatic viral replication on the natural history and clinical manifestations of chronic hepatitis C”. Grant from FONDECYT (National Fund of Science and Technology, Chile). N° 1050782. 2005-2008. Principal Investigator.

7. Grant of Center of Medical Research, Catholic University, for the study of “Cytokines in Non-Alcoholic Steato-Hepatitis”, 1999.

8. Grant of Center of Medical Research, Catholic University, for the study of “Hepatitis G Virus Prevalence in Chilean Hemophiliacs”, 1998.

Participation in Clinical Trials

1. A Randomized, Open-Labeled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered With Ribavirin Compared to Telaprevir Co-administered With Pegylated Interferon α-2a and Ribavirin in Treatment-Experienced Adults With Chronic Hepatitis C Genotype 1 Virus Infection (MALACHITE-II). Abbvie 2012. Local principal investigator.

2. A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered With and Without Ribavirin Compared to Telaprevir Co-administered With Pegylated Interferon α-2a and Ribavirin in Treatment-Naïve Adults With Chronic Hepatitis C Genotype 1 Virus Infection (MALACHITE I). Abbvie 2012. Local principal investigator.

3. A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects (Protocol No. P07755) (also known as MK-3034-040-00). Merck 2011-2014. Local principal investigator.

4. An international multicenter study evaluating the correlation of genotypes of IL28B with features of chronic hepatitis C and the demographics of patients. Roche 2011. Local principal investigator.

5. A Study of Vaniprevir (MK-7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028). Merck 2010-2011. Local principal investigator.

6. A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of 4 Different Regimens of MK-7009 When Administered Concomitantly with Pegylated Interferon and Ribavirin in Treatment-Experienced Patients with Chronic Genotype 1 Hepatitis C Virus Infection (MK-7009-009). Merck 2009-2011. Local principal investigator.

7. A phase II randomized, placebo-controlled study to evaluate the safety and efficacy of MK-7009 administered concomitantly with pegylated-interferon and ribavirin for 28 days in treatment-näive patients with chronic genotype 1 hepatitis C infection (MK-7009-007). Merck. 2008-2010. Local principal investigator.

8. Protocol 03-DK-0136. Low dose peginterferon and ribavirin therapy for patients with chronic hepatitis C infected with genotype 2 or 3. This clinical trial was designed to study the efficacy of an optimized treatment approach of hepatitis C in patients with a favorable profile of response. Principal Investigator.

9. Protocol 00-DK-0125. Immunogenetics of Hepatitis C Virus Infection. This project aims to study genetic factors influencing treatment response, progression and outcomes of chronic hepatitis C. Associate Investigator.

10. Protocol 02-DK-0072. Pilot Studies of Gamma Interferon Therapy for Chronic Hepatitis C. Associate Investigator.

11. Protocol 02-DK-0065. Combination of Pegylated Interferon and Ribavirin as Therapy for Patients with Chronic Hepatitis C with and without Renal Disease. Associate Investigator.

12. Protocol 01-DK-0247. Treatment of Chronic Delta Hepatitis with Pegylated Interferon. Associate Investigator.

13. Protocol 01-DK-0246. Combination of Lamivudine and Adefovir Dipivoxil for Treatment of Chronic Hepatitis B. Associate Investigator.

14. Protocol 01-DK-0130. Treatment of Nonalcoholic Steatohepatitis with Pioglitazone. Associate Investigator.

15. Protocol 00-DK-0186. The Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial: A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Long-Term Peginterferon Alpha 2a for Treatment of Chronic Hepatitis C in Patients who Failed to Respond to Previous Interferon Therapy. Associate Investigator.

16. Protocol 99-DK-0042. Long-Term Therapy with Ribavirin for Chronic Hepatitis C. Associate Investigator.

17. Protocol 95-DK-0199. Lamivudine for Chronic Hepatitis B. Associate Investigator.